5-hydroxy-7-morpholino-2-phenyl-4H-chromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5-hydroxy-7-morpholino-2-phenyl-4H-chromen-4-one
• 英文别名: 5-Hydroxy-7-morpholin-4-yl-2-phenyl-chromen-4-one；5-hydroxy-7-morpholin-4-yl-2-phenylchromen-4-one
• 化学式: C₁₉H₁₇NO₄
• 分子量: 323.348
• InChiKey: QLCYMYHLQRGYAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-hydroxy-7-morpholino-2-phenyl-4H-chromen-4-one 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以57%的产率得到5-((1-methyl-2-nitro-1H-imidazol-5-yl)methoxy)-7-morpholino-2-phenyl-4H-chromen-4-one
  参考文献：
  名称：

  Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361

  摘要：

  DNA-dependent protein kinase (DNA-PK) plays a key role in repair of radiation-induced DNA double strand breaks (DSB) by non-homologous end-joining. DNA-PK inhibitors (DNA-PKi) are therefore efficient radiosensitisers, but normal tissue radiosensitisation represents a risk for their use in radiation oncology. Here we describe a novel prodrug, SN38023, that is metabolised to a potent DNA-PKi (IC87361) selectively in radioresistant hypoxic cells. DNA-PK inhibitory potency of SN38023 was 24-fold lower than IC87361 in cell-free assays, consistent with molecular modelling studies suggesting that SN38023 is unable to occupy one of the predicted DNA-PK binding modes of IC87361. One-electron reduction of the prodrug by radiolysis of anoxic formate solutions, and by metabolic reduction in anoxic HCT116/POR cells that overexpress cytochrome P450 oxidoreductase (POR), generated IC87361 efficiently as assessed by LC-MS. SN38023 inhibited radiation-induced Ser2056 autophosphorylation of DNA-PK catalytic subunit and radiosensitised HCT116/POR and UT-SCC54C cells selectively under anoxia. SN38023 was an effective radiosensitiser in anoxic HCT116 spheroids, demonstrating potential for penetration into hypoxic tumour tissue, but in spheroid co-cultures of high-POR and POR-null cells it showed no evidence of bystander effects resulting from local diffusion of IC87361. Pharmacokinetics of IC87361 and SN38023 at maximum achievable doses in NIH-III mice demonstrated suboptimal exposure of UT-SCC-54C tumour xenografts and did not provide significant tumour radiosensitisation. In conclusion, SN38023 has potential for exploiting hypoxia for selective delivery of a potent DNA-PKi to the most radioresistant subpopulation of cells in tumours. However, prodrugs providing improved systemic pharmacokinetics and that release DNA-PKi that elicit bystander effects are needed to maximise therapeutic utility.

  DOI：

  10.1016/j.bcp.2019.113641
• 作为产物：
  描述：

  白杨素 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 18.33h， 生成 5-hydroxy-7-morpholino-2-phenyl-4H-chromen-4-one
  参考文献：
  名称：

  黑草 Phi 类谷胱甘肽转移酶的类黄酮抑制剂可对抗多种除草剂抗性

  摘要：

  禾本科杂草多重除草剂抗性（MHR）的进化和增长继续威胁着全球谷物生产。虽然多种过程可能导致耐药性，但早期的工作已将 phi 类谷胱甘肽-S-转移酶 ( Am GSTF1) 确定为黑草 ( Alopecurus myosuroides ) 中 MHR 的功能性生物标志物。这项研究结合化学和结构生物学，进一步深入了解Am GSTF1 在 MHR 中的作用。获得了野生型Am GSTF1 的晶体结构，以及两个专门设计的变体，这些变体允许与Am GSTF1 抑制剂 4-氯-7-硝基-苯并呋喃 (NBD-Cl) 的谷胱甘肽和谷胱甘肽加合物进行共晶结构测定。这些研究表明NBD-Cl的抑制活性与活性位点的封闭和底物结合的阻碍有关。使用配体钓鱼实验寻找Am GSTF1 的其他选择性抑制剂，确定了许多黄酮类化合物作为潜在的配体。随后使用黑草提取物进行的实验发现了一种特定的黄酮类化合物作为重组酶的天然配体。制备

  DOI：

  10.1039/d1ob01802g

文献信息

• Materials and methods to potentiate cancer treatment
  申请人：——

  公开号：US20020165218A1

  公开（公告）日：2002-11-07

  Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.

  抑制DNA依赖性蛋白激酶的化合物，包含这些化合物的组合物，抑制DNA-PK生物活性的方法，使细胞对引起DNA损伤的药物敏感的方法，以及增强癌症治疗的方法被披露。
• MAPK/ERK KINASE INHIBITORS
  申请人：Adams Mark E.

  公开号：US20080312307A1

  公开（公告）日：2008-12-18

  Compounds are provided for inhibition of MEK that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供了一些用于抑制MEK的化合物，其中变量的定义如下。此外，还提供了包含这些化合物的药物组合物、工具箱和制造物品；用于制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75
  作者：Bo-Wen Li、Feng-Hua Zhang、Erik Serrao、Huan Chen、Tino W. Sanchez、Liu-Meng Yang、Nouri Neamati、Yong-Tang Zheng、Hui Wang、Ya-Qiu Long

  DOI：10.1016/j.bmc.2014.04.016

  日期：2014.6

  HIV integrase (IN) is an essential enzyme for the viral replication. Currently, three IN inhibitors have been approved for treating HIV-1 infection. All three drugs selectively inhibit the strand transfer reaction by chelating a divalent metal ion in the enzyme active site. Flavonoids are a well-known class of natural products endowed with versatile biological activities. Their beta-ketoenol or catechol structures can serve as a metal chelation motif and be exploited for the design of novel IN inhibitors. Using the metal chelation as a common pharmacophore, we introduced appropriate hydrophobic moieties into the flavonol core to design natural product-based novel IN inhibitors. We developed selective and efficient syntheses to generate a series of mono 3/5/7/3'/4'-substituted flavonoid derivatives. Most of these new compounds showed excellent HIV-1 IN inhibitory activity in enzyme-based assays and protected against HIV-1 infection in cell-based assays. The 7-morpholino substituted 7c showed effective antiviral activity (EC50 = 0.826 mu g/mL) and high therapeutic index (TI > 242). More significantly, these hydroxyflavones block the IN-LEDGF/p75 interaction with low-to sub-micromolar IC50 values and represent a novel scaffold to design new generation of drugs simultaneously targeting the catalytic site as well as protein-protein interaction domains. (C) 2014 Elsevier Ltd. All rights reserved.
• MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT
  申请人：ICOS CORPORATION

  公开号：EP1351946A2

  公开（公告）日：2003-10-15
• DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION
  申请人：Chung Jay Hang

  公开号：US20100130597A1

  公开（公告）日：2010-05-27

  The invention relates to new functions of the DNA-PKcs gene product in energy metabolism, brain function and physical fitness.